Richard Aplenc
Impact in
- Oncology top 0.1%
- CAR-T cell therapy research
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
Papers in
- Hematology 142
- Acute Myeloid Leukemia Research 111
- Hematopoietic Stem Cell Transplantation 33
- Multiple Myeloma Research and Treatments 21
-
- Childhood Cancer Survivors' Quality of Life 76
- Co-authors
- Stephan A. GruppSusan R. RheingoldDavid T. TeacheyDavid M. BarrettCarl H. JuneBruce L. LevineDavid L. PorterAnne Chew
- Journals
- Blood (90 papers)Pediatric Blood & Cancer (46 papers)Journal of Clinical Oncology (33 papers)British Journal of Haematology (7 papers)Blood Advances (7 papers)
- Partner nations
- United StatesCanadaNetherlands
In The Last Decade
Richard Aplenc
307 papers receiving 13.1k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 8.1k
- Hematology 2.7k
- Immunology 2.9k
- Public Health, Environmental and Occupational Health 2.4k
- Genetics 2.2k
Countries citing papers authored by Richard Aplenc
This map shows the geographic impact of Richard Aplenc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Aplenc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Aplenc more than expected).
Fields of papers citing papers by Richard Aplenc
This network shows the impact of papers produced by Richard Aplenc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Aplenc. The network helps show where Richard Aplenc may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard Aplenc, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 33 | |
| 7 | 2023 | 2 | |
| 8 | 2021 | 57 | |
| 9 | 2021 | 26 | |
| 10 | 2021 | 38 | |
| 11 | 2019 | 39 | |
| 12 | 2019 | 39 | |
| 13 | 2017 | 20 | |
| 14 | 2017 | 1 | |
| 15 | 2017 | 6 | |
| 16 | 2015 | 42 | |
| 17 | 2015 | 35 | |
| 18 | Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 Hit paper breakdown → | 2014 | 313 |
| 19 | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy Hit paper breakdown → | 2013 | 459 |
| 20 | 2009 | 45 |
About Richard Aplenc
Richard Aplenc is a scholar working on Hematology, Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health, Oncology and Genetics, having authored 320 papers that have together received 13.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (111 papers), Acute Lymphoblastic Leukemia research (107 papers), Childhood Cancer Survivors' Quality of Life (76 papers), Neutropenia and Cancer Infections (58 papers), Hematopoietic Stem Cell Transplantation (33 papers), CAR-T cell therapy research (25 papers), Multiple Myeloma Research and Treatments (21 papers) and Protein Degradation and Inhibitors (20 papers). The work is most often cited by research in Oncology (8.1k citations), Hematology (2.7k citations), Immunology (2.9k citations), Public Health, Environmental and Occupational Health (2.4k citations) and Genetics (2.2k citations). Richard Aplenc has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Stephan A. Grupp, Susan R. Rheingold, David T. Teachey, David M. Barrett, Carl H. June, Bruce L. Levine, David L. Porter, Anne Chew, Shannon L. Maude and Nancy Bunin. Their work appears in journals such as Blood, Pediatric Blood & Cancer, Journal of Clinical Oncology, British Journal of Haematology and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.